IL-UNITAS-GLOBAL
22.2.2021 14:03:13 CET | Business Wire | Press release
Unitas Global announces the availability of Unitas Reach™ , the first global software defined network (SDN) to offer automated ubiquitous edge access to any cloud location. Enterprises are finding that current networks are a bottleneck to the adoption of new technologies and capabilities – these problems have not been resolved, until now. Unitas Reach™ is the industry's first purpose-built network connecting cloud providers, carrier-neutral data centers, SaaS applications, and edge access networks to form a multi-service global interconnection fabric.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005156/en/
"Organizations today need flexible, proven, and secure infrastructure to run their enterprise applications and multi-cloud solutions," shares Patrick Shutt, CEO of Unitas Global. "With Unitas Reach™, our clients achieve cost-optimized network connectivity with the agility needed to scale quickly and support the growing demands of applications on network architectures, performance, and costs."
Unitas Reach™ is built to provide connectivity options that different modern cloud services require with simple integration to traditional enterprise networks. With its presence on six continents, Unitas Reach™ provides redundant and diverse Internet, IP, Ethernet, and Wave access to distributed applications across any cloud, hybrid-cloud, multi-cloud, or private cloud destination. Strategic interconnections with hundreds of other networks and fiber access providers further extends the network access to the edge, including over 900 carrier neutral data centers and 30 million enterprise locations in over 85 countries. Sophisticated automation, monitoring, and orchestration to the edge make the entire interconnect fabric unmatched in enabling complete flexibility in service creation and scaling capacity as enterprise networking needs change.
"We designed Unitas Reach™ in response to the dynamic networking requirements that today's businesses require and have yet to experience," comments Grant Kirkwood, Founder and CTO of Unitas Global. "Providers and enterprises can easily add connectivity to dynamically support their ever changing network strategies, and customize capabilities to their unique set of service delivery, operations, access and configuration requirements.”
Unitas' edge to everywhere connectivity solutions offer providers and enterprises with automated:
- Cloud On-ramps™ for multi-cloud delivery
- High performance managed Internet
- Direct connectivity to and between multi-cloud platforms
- Agile and scalable WAN solutions
Unitas Reach™ provides the greatest choice and ease of use for provisioning enterprises with connectivity that delivers agile, cost-effective, low-latency connections to optimize application performance. Unitas Global solves the enterprise challenge by going to market with MSPs, hyperscalers, and data centers who are able to establish an on-net point of presence with Unitas Reach™ to expand their network coverage, scale services everywhere, and locate applications as close to customers as possible to improve performance and optimize costs.
Learn more about Unitas Reach™ and its edge to everywhere connectivity solution.
About Unitas Global
Unitas Global is a global managed network service provider offering automated ubiquitous edge access to any cloud, everywhere. The company provides the most agile connected multi-cloud environments that are easy-to-consume, fully managed, and backed by a promise to deliver the best application performance. Connect with Unitas at LinkedIn , Twitter , and its Blog .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005156/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom